



Attorney Ref: 385A US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Group Art Unit:	1632	MAY 16 2001
Examiner:	Paras	TECH CENTER 1600-2900
Applicant:	Clemons et al.	
Serial No.:	09/435,257	
Filed:	November 5, 1999	
For:	<i>FK506-Based Regulation of Biological Events</i>	

Assistant Commissioner of Patent  
Washington, DC 20231

May 9, 2001

**Sequence Compliance and Amendment to Sequence Listing**

In response to the Office Communication dated April 9, 2001, applicant submits amendments to the Specification and the Sequence Listing in compliance with 37CFR 1.821 through 1.825. Sequence ID numbers have been inserted in the amended Specification in a "clean version" followed by a "marked up version".

Please amend the Nucleotide/Amino Acid Sequence Listing by replacing it with the new enclosed Statement, Paper Copy and CRF Diskette in accordance with 37 CFR §1.821(a), 1.821(f) and 1.821(g). This amendment does not introduce any new matter. No additional costs are believed to be due in connection with this amendment. However, should any such fees be due, please charge them to our Deposit Account No. 01-2315.

**Amendment to Specification**

Please amend the specification to include Sequence ID numbers as follows:

- Beginning on page 36, line 18, (ending on page 37) replace the paragraph in the specification with the following:

The fusion proteins may contain as a heterologous domain a cellular localization domain such as a membrane retention domain. See e.g. PCT/US94/01617, especially pages 26-27. Briefly, a membrane retention domain can be isolated from any convenient membrane-bound protein, whether endogenous to the host cell or not. The membrane retention domain may be a transmembrane retention domain, i.e., an